Colorectal cancer
Conditions
Interventions
Group TJ:Tegileridine fumarate
Group SF:Sufentanil
Sponsors
The First Affiliated Hospital of the University of South China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years, regardless of gender. 2.American Society of Anesthesiologists (ASA) physical status classification of I to III. 3.Body Mass Index (BMI) between 18 kg/m^2 and 25 kg/m^2, inclusive. 4.Scheduled for elective laparoscopic radical resection of colorectal cancer under general anesthesia. 5.Requiring postoperative analgesia and providing consent to participate in this trial.
Exclusion criteria
Exclusion criteria: 1.Patients unable to cooperate due to language barriers, mental disorders, or other similar reasons. 2.Patients with a known allergy to any drug used in the study. 3.Chronic users of opioid or psychotropic medications. 4.Patients with severe cardiac diseases, such as third-degree atrioventricular block, coronary heart disease, etc. 5.Patients with severe pulmonary diseases, such as acute exacerbation of chronic obstructive pulmonary disease, severe bronchiectasis, etc. 6.Patients with pre-operative metastasis or those who have undergone prior radiotherapy or chemotherapy. 7.Patients deemed by the investigator to be unsuitable for participation for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 15-item Quality of Recovery Scale (QoR-15) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dosage of Parecoxib for Rescue Analgesia;The number of PCA demands ;Causality Assessment of Adverse Events in Relation to the Investigational Product (during the Clinical Trial);Subject Satisfaction Score with Pain Relief;Investigator Satisfaction Score; | — |
Countries
China
Contacts
Public ContactChao Li
The First Affiliated Hospital of the University of South China
Outcome results
None listed